Attard, Gerhardt; Sydes, Matthew R; Mason, Malcolm D; Clarke, Noel W; Aebersold, Daniel; de Bono, Johann S; Dearnaley, David P; Parker, Chris C; Ritchie, Alastair W S; Russell, J Martin; Thalmann, George; Cassoly, Estelle; Millman, Robin; Matheson, David; Schiavone, Francesca; Spears, Melissa R; Parmar, Mahesh K B; James, Nicholas D (2014). Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European urology, 66(5), pp. 799-802. Elsevier 10.1016/j.eururo.2014.05.038
|
Text
1-s2.0-S030228381400520X-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (933kB) | Preview |
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology |
UniBE Contributor: |
Aebersold, Daniel Matthias, Thalmann, George |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0302-2838 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Beatrice Scheidegger |
Date Deposited: |
10 Mar 2015 16:33 |
Last Modified: |
02 Mar 2023 23:25 |
Publisher DOI: |
10.1016/j.eururo.2014.05.038 |
PubMed ID: |
24985962 |
BORIS DOI: |
10.7892/boris.61607 |
URI: |
https://boris.unibe.ch/id/eprint/61607 |
Actions (login required)
 |
Edit item |